Status:
COMPLETED
Impact of Ketoflex 12/3 Diet on Early-to-Mid Stage Alzheimer's Progression
Lead Sponsor:
Prof. Lutfu Hanoglu, MD
Conditions:
Alzheimer Type Dementia
Alzheimer's Disease (AD)
Eligibility:
All Genders
50-85 years
Phase:
NA
Brief Summary
This study investigates the effects of the Ketoflex 12/3 diet on the clinical progression of early-to-mid stage Alzheimer's disease. The study evaluates cognitive function, metabolic changes, and over...
Eligibility Criteria
Inclusion
- Age between 50-85 years
- Clinical Dementia Rating (CDR) score of 0.5 or 1
- Diagnosis of Alzheimer's disease (AD) according to NINCDS-ADRDA criteria
Exclusion
- Alcohol and/or substance dependence
- Diagnosis of chronic renal failure
- Diagnosis of another neuropsychiatric disorder
- Presence of amalgam dental fillings and/or failure to have them removed following the SMART protocol
Key Trial Info
Start Date :
March 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 31 2024
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06898424
Start Date
March 1 2024
End Date
October 31 2024
Last Update
April 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Istanbul Medipol Universitesi
Istanbul, Turkey (Türkiye), 34214